Calcifediol
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Calcifediol: From Vitamin D Supplementation to Vitamin D Deficiency
One-Sentence Summary
Calcifediol (25-hydroxyvitamin D3, 25(OH)D3) is the principal circulating metabolite of vitamin D3, used clinically for vitamin D supplementation and secondary hyperparathyroidism management in chronic kidney disease. The TxGNN model predicts it may be effective for Vitamin D Deficiency with a near-perfect score of 99.99%, essentially validating the drug’s established pharmacological role. No clinical trials or publications were retrieved for this specific query, likely due to an obsolete disease ontology term being used — not due to an absence of real-world evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in regulatory database |
| Predicted New Indication | Vitamin D Deficiency |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| US Market Status | Not marketed (0 licenses found) |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence package. Based on well-established pharmacology, calcifediol is 25-hydroxyvitamin D3 — the main circulating form of vitamin D produced by hepatic CYP2R1/CYP27A1-mediated hydroxylation of cholecalciferol (vitamin D3). It is the direct substrate for renal CYP27B1 (1α-hydroxylase), which converts it to calcitriol (1,25(OH)2D3), the biologically active hormonal form that binds the vitamin D receptor (VDR) to regulate calcium homeostasis, bone mineralization, and immune function.
Vitamin D deficiency (serum 25(OH)D < 20 ng/mL) affects over 1 billion people worldwide. Calcifediol offers clinical advantages over standard cholecalciferol supplementation: it bypasses intestinal absorption bottlenecks (particularly useful in fat malabsorption syndromes), achieves faster and more predictable elevation of serum 25(OH)D, and can be used when hepatic 25-hydroxylation is impaired. The drug’s repurposing rationale embedded in this evidence package captures this precisely — calcifediol directly replaces the deficient circulating metabolite, making it mechanistically the most direct treatment for vitamin D deficiency.
The near-perfect TxGNN prediction score (99.99%) for vitamin D deficiency represents model validation rather than a novel repurposing signal. More compelling repurposing opportunities appear at lower ranks: particularly vitamin D-dependent rickets Type 1B (VDDR1B, CYP2R1 deficiency, rank 4), where calcifediol directly bypasses the defective hepatic 25-hydroxylation step and represents a mechanistically distinct indication with actual clinical trial and publication support.
Clinical Trial Evidence
Currently no related clinical trials registered for calcifediol queried against the disease term “obsolete vitamin D deficiency.” This reflects an ontology mismatch — the query used a retired disease term, not an absence of clinical evidence in the field. Re-querying under active terminology (e.g., “vitamin D insufficiency,” “hypovitaminosis D”) would be expected to yield substantial results.
Literature Evidence
Currently no related literature available for the specific query combination used. Published evidence for calcifediol in vitamin D deficiency management is well-established but was not retrieved under this evidence pack’s query parameters.
US Market Information
No regulatory approvals were found for calcifediol in the US regulatory database queried for this report (0 licenses, market status: not marketed). This is likely a data gap rather than a true absence — calcifediol has documented regulatory history under the brand name Rayaldee and warrants a direct regulatory database verification as a remediation step.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The TxGNN model’s L1-confidence prediction for vitamin D deficiency aligns with calcifediol’s core pharmacological mechanism as a circulating vitamin D metabolite, and the clinical evidence base in this therapeutic area is extensive — the data gap in this report reflects a search terminology issue, not a lack of supporting evidence.
To proceed, the following is needed:
- Re-run evidence query using active MeSH terminology (“vitamin D deficiency,” ICD-10 E55.9, “hypovitaminosis D”) to retrieve actual clinical trial and publication records — current returns of zero are an artifact of the obsolete disease term
- Confirm US regulatory status (verify Rayaldee NDA records directly via FDA Orange Book or Drugs@FDA; DG001 remediation)
- Obtain DrugBank MOA data (DG002 remediation via DrugBank API) to complete mechanistic analysis
- Evaluate VDDR Type 1B (CYP2R1 deficiency) as a separate, mechanistically-driven repurposing target: calcifediol directly compensates for defective hepatic 25-hydroxylation in this rare genetic disorder, representing a more genuinely novel clinical opportunity than general vitamin D deficiency treatment
- Safety profile review: obtain TFDA/FDA package insert warnings and contraindications before any clinical development planning
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.